CytomX Therapeutics Files Definitive Proxy Statement
Ticker: CTMX · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
CytomX proxy filed - vote on directors & auditors soon.
AI Summary
CytomX Therapeutics, Inc. filed its definitive proxy statement on April 28, 2025, for its annual meeting of stockholders on June 11, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and governance matters, impacting the company's strategic direction.
Risk Assessment
Risk Level: low — This is a routine annual proxy filing, not indicating any immediate operational or financial distress.
Key Numbers
- 20250428 — Filing Date (Definitive Proxy Statement filed on this date.)
- 20250611 — Meeting Date (Annual meeting of stockholders.)
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- 0001140361-25-016026 (filing_id) — Accession Number
- 20250428 (date) — Filing Date
- 20250611 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit votes from shareholders for their annual or special meetings, providing details on matters to be voted upon, such as director elections and executive compensation.
When was CytomX Therapeutics' definitive proxy statement filed?
CytomX Therapeutics, Inc. filed its definitive proxy statement on April 28, 2025.
When is the scheduled date for CytomX Therapeutics' stockholder meeting?
The filing indicates that the annual meeting of stockholders is scheduled for June 11, 2025.
What is the company's primary business according to the filing?
CytomX Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where is CytomX Therapeutics, Inc. headquartered?
The company's business and mailing address is listed as 151 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding CytomX Therapeutics, Inc. (CTMX).